Complications of Aortic Thrombosis in Gastric Cancer Patients Post-Feeding Jejunostomy
Aortic thrombosis in gastric cancer patients after feeding jejunostomy is a rare but life-threatening complication that can lead to peripheral embolization, limb ischemia, visceral ischemia, and death—requiring immediate anticoagulation and potentially surgical intervention.
Primary Complications
Embolic Events
Aortic thrombosis poses severe embolic risks that directly threaten mortality:
- Limb ischemia from peripheral embolization 1
- Visceral ischemia affecting intestinal perfusion 1
- Stroke from proximal thrombus migration 1
- Renal and mesenteric malperfusion if thrombosis extends above renal arteries 1
Jejunostomy-Specific Complications
The feeding jejunostomy itself carries distinct risks that may compound the thrombotic state 2, 3:
- Non-occlusive mesenteric ischemia (NOMI): A lethal complication presenting 2-5 days postoperatively with abdominal distension, hypotension, and peritonitis, carrying 50% 30-day mortality 4
- Jejunal volvulus: Unique to jejunostomy placement 5
- Small bowel perforation 5
- Catheter-related complications (1.5-6% rate) 2
- Persistent enterocutaneous fistulas 5
Cancer-Associated Thrombotic Mechanisms
Gastric cancer creates a hypercoagulable state through multiple pathways 6, 7:
- Release of prothrombotic factors (tissue factor, mucin, cysteine protease) 8
- Tumor-driven inflammation 9
- Cisplatin-based chemotherapy specifically increases arterial thrombosis risk—the first reported case of aortic thrombosis during cisplatin therapy for gastric cancer demonstrated this direct association 7
Critical Management Algorithm
Immediate Recognition
High clinical suspicion is paramount when patients present with:
- Lower extremity pain, pallor, or pulselessness
- Abdominal pain with peritoneal signs
- Hypotension or shock
- Acute neurological deficits
Diagnostic Approach
- CT angiography is the gold standard for confirming aortic thrombosis and defining extent 1
- Assess for concurrent complications: bowel ischemia, renal/visceral malperfusion
- Laboratory evaluation: lactate (elevated in mesenteric ischemia), coagulation studies
Treatment Strategy
For acute symptomatic aortic thrombosis 1, 10:
- Immediate anticoagulation with LMWH unless contraindicated by active bleeding
- Surgical consultation for:
- Open embolectomy if embolic source
- Aorto-iliac reconstruction for atherosclerotic occlusion
- Bowel resection if intestinal infarction present 3
For cancer-associated thrombosis specifically 10:
- LMWH monotherapy is superior to warfarin in cancer patients (Category 1 evidence)
- Duration: minimum 3 months, indefinite if cancer remains active 10
- Monitor for recurrent thrombosis (18.5% rate in cancer patients not receiving anticoagulation) 11
Jejunostomy Feeding Modifications Post-Thrombosis
Critical feeding protocol to prevent NOMI 4, 2:
- Defer feeds during vasopressor support
- Start at 10-30 mL/h with low-strength formulation
- Escalate slowly over 5-7 days only if electrolytes stable
- Monitor intestinal tolerance closely
- Supplemental parenteral nutrition may be necessary 2
Specific Pitfalls to Avoid
Do not dismiss early abdominal symptoms in jejunostomy patients—NOMI presents with nonspecific signs but deteriorates rapidly 4
Do not use warfarin for cancer-associated thrombosis—LMWH demonstrates superior efficacy and safety 10
Do not rapidly escalate jejunostomy feeds in hemodynamically unstable patients—this precipitates ischemic bowel complications 2, 4
Do not delay surgical exploration if peritonitis or bowel infarction suspected—30-day mortality reaches 50% with delayed intervention 4
Bleeding Risk Considerations
The gastric cancer population faces competing risks 10:
- Anticoagulation is essential for thrombosis but increases bleeding risk
- Weigh risks individually: active GI bleeding, thrombocytopenia, recent surgery
- If anticoagulation contraindicated, reassess regularly for resolution of contraindications 1
- Consider inferior vena cava filter only in absolute anticoagulation contraindications (not routinely recommended)
Long-term Surveillance
For patients who survive the acute event 12:
- Continue anticoagulation indefinitely while cancer active
- Monitor for recurrent thrombosis (higher risk with metastatic disease, ongoing chemotherapy)
- Surveillance imaging at 1 year, then every 5 years if stable 12
The combination of gastric cancer, cisplatin chemotherapy, and feeding jejunostomy creates a perfect storm for thrombotic and ischemic complications—aggressive anticoagulation, cautious feeding protocols, and low threshold for surgical intervention are essential to reduce the 50% mortality associated with these complications.